Dupilumab and Crisaborole for Atopic Dermatitis: Effectiveness and Value

Voting Questions for May 25, 2017 Public Meeting

These questions are intended for the deliberation of the Midwest CEPAC voting body at the public meeting.

1) In patients with mild-to-moderate atopic dermatitis, is the evidence adequate to demonstrate that the net health benefit of treatment with crisaborole is greater than that of treatment with topical corticosteroids or topical calcineurin inhibitors?
   Yes    No

2) In adults with moderate-to-severe atopic dermatitis who have failed topical therapy, is the evidence adequate to demonstrate that treatment with dupilumab provides additional net health benefits beyond continued non-pharmacologic treatments such as emollients?
   Yes    No

3) In adults with moderate-to-severe atopic dermatitis who have failed topical therapy, is the evidence adequate to demonstrate that the net health benefit of treatment with dupilumab is greater than that of treatment with cyclosporine?
   Yes    No

4) Given the available evidence on comparative clinical effectiveness and incremental cost effectiveness, and considering other benefits, disadvantages, and contextual considerations, in a mixed population of adults with moderate-to-severe atopic dermatitis who have failed topical therapy, what is the long-term value for money of dupilumab compared with no systemic treatment?
   Low    Intermediate    High
5) Given the available evidence on comparative clinical effectiveness and incremental cost effectiveness, and considering other benefits, disadvantages, and contextual considerations, in adults with moderate atopic dermatitis who have failed topical therapy, what is the long-term value for money of dupilumab compared with no systemic treatment?

Low                  Intermediate            High

6) Given the available evidence on comparative clinical effectiveness and incremental cost effectiveness, and considering other benefits, disadvantages, and contextual considerations, in adults with severe atopic dermatitis who have failed topical therapy, what is the long-term value for money of dupilumab compared with no systemic treatment?

Low                  Intermediate            High